Autolus receives FDA RMAT designation for approved leukemia CAR-T in lupus
核心洞察
The FDA granted Regenerative Medicine Advanced Therapy designation to Autolus Therapeutics' obecabtagene autoleucel for systemic lupus erythematosus (搜索) and lupus nephritis (搜索).
The designation was supported by Phase 1b data from the CARLYSLE trial, with specific patient numbers, response rates and safety findings not disclosed.
Obe-cel is already approved as AUCATZYL for relapsed or refractory B-cell acute lymphoblastic leukemia (搜索), and the pivotal Phase 2 LUMINA trial is enrolling across five countries with data expected in 2028.
Autolus Therapeutics announced on September 9, 2026 that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for systemic lupus erythematosus (搜索) (SLE) and lupus nephritis (搜索) (LN). The company has dual headquarters in London and Gaithersburg, Maryland.
Obe-cel is a programmed T cell therapy already marketed as AUCATZYL for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (搜索). RMAT designation, created under the 21st Century Cures Act, is intended to accelerate development and regulatory review of regenerative medicine therapies for serious or life-threatening diseases. The announcement did not specify which RMAT benefits, such as early FDA interaction or rolling review, Autolus expects to use.
The designation was supported by Phase 1b data from the CARLYSLE trial, though patient numbers, response rates and safety findings from that study were not disclosed. Chief Development Officer Dr. Matthias Will said the designation provides a framework to facilitate efficient development within the LUMINA trial, a pivotal Phase 2 study currently enrolling patients across five countries with data expected in 2028. A positive result would extend obe-cel beyond its approved indication into autoimmune disease.